Warning: Attempt to read property "ID" on null in /home/oursymp/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php on line 212

Warning: Cannot modify header information - headers already sent by (output started at /home/oursymp/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php:212) in /home/oursymp/public_html/wp-content/plugins/modern-events-calendar-lite/app/libraries/main.php on line 3447

Warning: Cannot modify header information - headers already sent by (output started at /home/oursymp/public_html/wp-content/plugins/subscribe-to-comments/subscribe-to-comments.php:212) in /home/oursymp/public_html/wp-content/plugins/modern-events-calendar-lite/app/libraries/main.php on line 3448
BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH CALSCALE:GREGORIAN PRODID:-//WordPress - MECv6.5.5//EN X-ORIGINAL-URL:https://oursymposium.sites.unlv.edu/ X-WR-CALNAME:Office of Undergraduate Research (OUR) Fall 2021 Virtual Undergraduate Research Symposium X-WR-CALDESC: REFRESH-INTERVAL;VALUE=DURATION:PT1H X-PUBLISHED-TTL:PT1H X-MS-OLK-FORCEINSPECTOROPEN:TRUE BEGIN:VEVENT CLASS:PUBLIC DTSTART;TZID=UTC:20211115T000000 DTEND;TZID=UTC:20211120T000000 DTSTAMP:20211028T000000 UID:MEC-d3d80b656929a5bc0fa34381bf42fbdd@oursymposium.sites.unlv.edu CREATED:20211028 LAST-MODIFIED:20211110 PRIORITY:5 TRANSP:OPAQUE SUMMARY:HNSE-O2-3. Development of a Novel Alzheimer’s Therapy: Reduction of Inflammation DESCRIPTION:\n\nAurora Emini1\nLorena Samentar, Ph.D.1\nFaculty Mentor: Nora Caberoy, Ph.D.1\n1College of Sciences, Department of Life Sciences\nABSTRACT\nAlzheimer’s disease is a progressive neurodegenerative disease affecting about 5.8M Americans and nearly 48M people worldwide. Currently, there is no cure for Alzheimer’s. Available treatments only address the cognitive and behavioral symptoms but do not delay or stop the progression of the disease. One characteristic of Alzheimer’s is the deposition of amyloid beta plaques in the brain. Clearance of these plaques involves receptors on the cell surface whose activation results to the release of harmful inflammatory factors. This leads to the eventual death of nerve cells. At the Caberoy Lab, we develop a novel Alzheimer’s therapy through amyloid beta clearance without causing inflammation by using the hybrid protein that we have engineered. We have previously demonstrated that our hybrid facilitated amyloid beta clearance. So our main question here is, can our hybrid reduce inflammation in Alzheimer’s disease? We observe a significant reduction in levels of harmful oxidative and inflammatory factors in the presence of our hybrid compared to the control. This implies that our hybrid does not only facilitate clearance of plaques but also reduce inflammation. Our promising result is very exciting as we join the race in developing a cure for Alzheimer’s disease.\n URL:https://oursymposium.sites.unlv.edu/program/development-of-a-novel-alzheimers-therapy-reduction-of-inflammation/ ORGANIZER;CN=The Office of Undergraduate Research:MAILTO:our@unlv.edu CATEGORIES:Health & Natural Sciences & Engineering END:VEVENT END:VCALENDAR